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ABSTRACT 
OBJECTIVE. To analyse some ethical issues involved in umbilical cord blood (UCB) 
collection, storage and use.
MATERIALS AND METHODS. Ethical issues were addressed in the light of the well-
known fundamental ethical principles for biomedicine: beneficence/non maleficence, respect 
for autonomy and justice. Specific issues that have been debated concerning the clinical utility 
of autologous use compared with allogeneic use for transplantation, the validity of informed 
consent, especially in private UCB banking, and finally the controversial question of private 
UCB banking for-profit compared to public UCB banking non-profit.
RESULTS. Our ethical analysis has highlighted that the allogeneic UCB use for transplantation, 
compared to autologous UCB use, seems to fulfil the principle of beneficence/non maleficence 
as it provides “logistic” and clinical benefits and it decreases risks; the acquisition of informed 
consent requires some counselling, particularly for autologous collection; finally, public UCB 
banking seems to fulfil the criteria for justice more than private ones.
CONCLUSION. Present and future therapeutic UCB possibilities for treating a wide variety 
of diseases need to increase the number of UCB units available. For this purpose, a “gift” 
culture and a “solidarity chain” between donors and recipients are requested. Moreover, in 
recent years, a further and emerging model of bank seems usable, i.e. “hybrid” banking.
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Introduction 
Umbilical cord blood (UCB) is a rich source of multipotent stem cells with high 
regeneration capacities and potential differentiation into various tissue specific cells. 
So UCB stem cells are candidates for future use in treating a wide variety of diseases 
thanks to their potential in restoring hematopoietic, epithelial, endothelial and 
neural tissues both “in vitro” and “in vivo”1.
At the moment, UCB cells are successfully used to treat different hematologic 
malignancies, but their future applications in regenerative medicine are potentially 
greater and also include a large number of non-hematopoietic diseases, which are 
currently incurable.
In recent years, actual and potential successes in UCB transplantation and in 
regenerative medicine have generated popular/scientific expectations and an 
increasing interest in establishing and developing UCB banks worldwide, both 
public and private, for the storage of UCB units.
To 2014, more than 600.000 UCB units (data available on www.bmdw.org , www.
nmdp.org ) have been donated and stored in about 120 public banks for allogeneic 
use and they were included in a global network2,3. Furthermore, over 1.000.0004 
UCB units have been stored in many private banks for autologous (personal) use, 
and this number is rapidly growing. 
1 Rosenthal J, Woolfrey AE, Pawlowska, A et al, »Hematopoietic Cell Transplantation With Autologous Cord 
Blood in Patients With Severe Aplastic Anemia: An Opportunity to Revisit the Controversy Regarding Cord 
Blood Banking for Private Use«, Pediatr Blood Cancer, 2011, 56: 1009–12.
2 Gluckman E, Ruggeri A, Volt F et al, »Milestones in umbilical cord blood transplantation«, Br J Haematol. 
2011, 154 (4):441-7.
3 http://www.bmdw.org (19 March 2015).
4 Wagner AM, Krenger W, Suter E et al, »High acceptance rate of hybrid allogeneic-autologous umbilical cord 
blood banking among actual and potential Swiss donors«, Transfusion. 2013, 53(7):1510-9.
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Table I - Total number of cord blood units  
(available on http://www.bmdw.org/index.php?id=statistics_cordblood)
Compared to the number of related (sibling) and unrelated allogeneic UCB 
transplants (over 20.000), autologous transplants (about 100) still play a very 
limited role in the treatment of some specific diseases, as documented by the small 
number of clinical cases mostly with unknown outcomes5 (cf. Table II for the 
concepts of autologous and allogeneic).
5 Thornley I, Eapen M, Sung L et al, »Private cord blood banking: experiences and views of pediatric hemato-
poietic cell transplantation physicians«. Pediatrics, 2009, 123(3):1011-7. Ballen K, »Challenges in umbilical cord 
blood stem cell banking for stem cell reviews and reports«, Stem Cell Rev, 2010, 6: 8–14. Forraz N, McGuckin CP, 
»The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine«, Cell Prolif., 2011, 44 
(Suppl. 1): 60–9. Ferreira E, Pasternak J, Bacal N, et al, »Autologous cord blood transplantation«. Bone Marrow 
Transplant, 1999, 24:1041. Hayani A, Lampeter E, Viswanatha D, et al, »First report of autologous cord blood 
transplantation in the treatment of a child with leukaemia«. Pediatrics, 2007, 119: e296–e300.
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Table II - Glossary
ALLOGENEIC AUTOLOGOUS
Donor and recipient are different: 
UCB stem cells  
are obtained from a donor  
and suitable for the infusion 
in another person (related or not related)
Donor and recipient are 
identical: 
UCB stem cells  
are taken and applied  
in the same person
Legenda 
UCB = umbilical cord blood
The use of UCB cells (particularly their collection and storage) raise some ethical 
issues6. They were methodologically addressed in the light of the well-known 
fundamental ethical principles of biomedicine: the principles of beneficence/non 
maleficence, the principle of autonomy and the principle of justice. 
Particularly, the following issues will be debated: a) clinical appropriateness and 
beneficence/non maleficence of UCB allogeneic donation or autologous storage for 
transplantation; b) validity of informed consent (IC) to UCB donation/storage; c) 
the economic issue in private UCB banking. 
1.  Clinical appropriateness and beneficence/non maleficence 
of UCB allogeneic donation or autologous storage for 
transplantation 
The first requirement for assessing the ethical acceptability of any treatment is to 
assess the balance between benefits for patients and for society, and the risks of 
adverse effects (principle of beneficence/non maleficence). 
According to Rocha and Locatelli in 20087, there are substantial “logistic” and 
clinical benefits in UCB allogeneic use, compared to other stem cell sources for 
allogeneic hematologic stem cells transplantation (HSCT)8:
6 Skene L, »Development of stem cells from umbilical cord blood and blood banking: “non-controversial” and 
“free of political and ethical debate”?«, J Law Med, 2012, 19: 490-6.
7 Rocha V, Locatelli F, »Searching for alternative hematopoietic stem cell donors for pediatric patients«, Bone 
Marrow Transplant, 2008, 41: 207–14.
8 Rocha V, Gluckman E, »Improving outcomes of cord blood transplantation: HLA matching, cell dose and 
other graft- and transplantation-related factors«, British Journal of Haematology, 2009, 147: 262–74.
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(i) significantly faster availability of banked cryo-preserved UCB units, with 
patients receiving UCBT a median of 25–36 days earlier than those receiving 
an unrelated bone marrow graft;
(ii) extension of the donor pool due to tolerance of 1–2 Human Leucocyte 
Antigen (HLA) mismatches out of six;
(iii) lower incidence and severity of acute graft-versus-host disease (GVHD);
(iv) lower risk of transmitting infections by latent viruses, such as cytomegalovirus 
(CMV) and Epstein–Barr virus (EBV);
(v) lack of risk to the donor;
(vi) higher frequency of rare haplotypes compared to bone marrow registries, 
because it is easier to target ethnic minorities.
Nevertheless, there are some possible disadvantages in UCB use. As discussed by 
Samuel et al.9, UCB contains a limited cell dose; it presents higher graft failure rates 
and a lower speed of hematopoietic stem cell recovery as well as a higher rate of 
infection. Advantages and disadvantages are highlighted in Table III.
Table III - UCB stem cells use: advantages vs disadvatages  
(in comparison to other sources of allogeneic HSCT)
9 Samuel GN, Kerridge IH, O’Brien TA, »Umbilical cord blood banking«, MJA, 2008, 188:533-5.
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Recent evidences suggest that these disadvantages will be improved through the co-
transplantation of two UCB units from different donors (“double cord” transplant) 
and the expansion of the volume of cord blood protocols (increasing the number of 
stem cells). 
Moreover, recent findings on graft engineering and underway studies are currently 
evaluating the feasibility of “ex vivo” expansion of the units.10
Certainly, the growing and recognized value of UCB transplantation is supported 
by existing clinical practice and a range of studies. The clinical use of UCB may also 
become the front-line treatment for children suffering from leukaemia11.
Finally, recent clinical studies extend the potential of neonatal stem cells for clinical 
applications beyond haematotherapies to autoimmune disorders, cerebral palsy and 
type I diabetes12.
Therefore, on the basis of these considerations, the allogeneic use of UCB stem cells 
seems fulfil the principle of beneficence. In fact, as also pointed by Di Sciascio et al. 
“they have the stated goal of curing or effectively controlling diseases that cannot be 
managed with current treatment protocols. Therefore, the intentions of those who 
intend to use the stem cells qualify in principle as positive, reflecting also a classic 
aspect of medical ethics: the protection of life and health of the patient”13.
The absence of a clear and effective therapeutic indication to autologous UCB use 
that negates the purpose of the beneficence, which is intrinsic to allogeneic UCB 
donation and that would give a first indication of the autologous storage. Physical 
life is the first fundamental value of the person. So, it follows that we should 
prioritize respect for life in the ethical evaluation of the current or future use of any 
treatment, or even its storage.
Here the complex and multidimensional concept of “appropriateness”14 comes in.
10 Escalo´n MP, Komanduri K, »Cord blood transplantation: evolving strategies to improve engraftment and 
immune reconstitution«, Curr Opin Oncol, 2010, 22: 122–9. Delaney C, Heimfeld S, Brashem-Stein C, et al, 
»Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution«, Nat 
Med, 2010, 16: 232–6.
11 Stanevsky A, Goldstein G, Nagler A, »Umbilical cord blood transplantation: pros, cons and beyond«, Blood 
Rev. 2009, 23: 199-204. Holland P, Mc Cauley C, »Private Cord Blood Banking-current use and clinical future«, 
Stem Cell Rev and Rep, 2009, 5:195-203.
12 Forraz N, McGuckin CP, »The umbilical cord: a rich and ethical stem cell source to advance regenerative 
medicine«, Cell Prolif, 2011, 44 (Suppl. 1): 60–9.
13 Di Sciascio G, Tambone V, Sacchini D, »Sull’utilizzo delle cellule staminali a fini terapeutici e le fonti della 
moralità«, Clin Ter, 2007, 158: 21-5.
14 Art 3 of Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the 
Application of Biology and Medicine: Convention on Human Rights and Biomedicine. (Oviedo 1997). http://con-
ventions.coe.int/Treaty/en/Treaties/Html/164.htm (19 March 2015); Dipartimento della Programmazione e 
dell’ordinamento del Servizio Sanitario Nazionale. Direzione Generale della Programmazione Sanitaria, Ufficio 
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A cure can be considered “appropriate” when it is associated with a net benefit or 
when it maximizes the benefit and minimizes the risk to the patient. Therefore, a 
treatment is “appropriate” when it fulfils the effective clinical indications, at the 
right time, in an adequate manner, for the patient’s benefit. 
Without these essential elements of proven effectiveness and net benefit to the 
patient a treatment is “inappropriate”., Autologous UCB use would be considered 
“inappropriate” for the following reasons: its limited clinical applications to 
particular types of diseases and in particular stages of disease; the very low 
probability of using UCB stem cells - between 0,04% (1: 2.500) to 0,0005% (1: 
200.000) - during the first 20 years15; the fact that autologous transplants are not 
recommended for hereditary or oncohaematological diseases16, because cord blood 
cells might be already be bearers of the disease markers without benefit, but with 
harm to the patient; little available information whether the internationally accepted 
quality criteria for stored samples are met17; the uncertain shelf life of stored UCB 
samples; the regenerative medicine perspectives are still widely hypothetical or in 
initial trials.
Moral obligation also requires respecting the principle of non-maleficence, i.e. the 
Hippocratic primum non nocere (first do not harm).
Concerning the recipient, it has not been proved that UCB transplantation implies 
a greater risk than transplantation using bone marrow-derived hematopoietic stem 
cells or peripheral blood stem cells. 
In the same way, the literature shows that no risk is associated with the donation, 
neither for the mother nor for the child, since the umbilical cord cut and blood 
collection is fully compatible with proper care for the newborn.
However, a point that is still debated is the timing of umbilical cord clamping, 
especially for what concerns the assessment of the optimal time to clamp the 
III Ex D.G.Progs. Manuale di formazione per il governo clinico: Appropriatezza. (July 2012). http://www.salute.gov.
it/imgs/C_17_pubblicazioni_1826_allegato.pdf (19 March 2015). Consiglio d’Europa, Comitato Dei Ministri, 
Raccomandazione N.° R (97) 17 del Comitato dei Ministri agli Stati Membri: Sullo Sviluppo e l’Attivazione di 
Sistemi di Miglioramento della Qualità (Smq) dell’Assistenza Sanitaria. http://www.salute.gov.it/imgs/C_17_pub-
blicazioni_28_allegato.pdf (19 March 2015); Ministero Del Lavoro, Della Salute E Delle Politiche Sociali. Uso ap-
propriato delle cellule staminali del sangue del cordone ombelicale – Elementi informativi essenziali. (18 March 2009). 
http://www.trapianti.salute.gov.it/imgs/C_17_pubblicazioni_941_allegato.pdf (19 March 2015).
15 Ballen KK, Barker JN, Stewart SK et al, »American Society for Blood and marrow Transplantation (Asbmt) 
Committee Report - Collection and Preservation of Cord Blood for Personal Use«, Biol Blood Marrow Transplant, 
2008, 14:356-363; Nietfeld FF, Pasquini MC, Logan BR, et al, »Lifetime Probabilities of Hematopoietic Stem Cell 
Transplantation in the U.S.« Biol Blood Marrow Transplant, 2008, 14:316-322.
16 McKenna D, Sheth J, »Umbilical cord blood: current status & promise for the future«. Indian J Med Res, 
2011, 134:261-9.
17 Spurr EE et al, »Cryopreserved human haematopoietic stem cells retain engraftment potential after ex- tended 
(5-14 years) cryostorage«, Cryobiology, 2002, 44 (3):210, 2002.
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umbilical cord in preterm and full-term newborns without causing any harm to the 
child, which could be deprived of a significant quantity of blood, iron, and other 
benefits in the case of early procedure.
Some reviews of randomized controlled trials (RCTs)18, comparing the effects of 
early and late cord clamping on maternal and infant outcomes, have showed that 
delayed cord clamping (at least 2 minutes after birth) appears beneficial for 
preterm19 and full-term newborns: it improves both the short- and long-term 
hematologic and iron status of full-term infants.
On the other hand, some observational studies suggest that delayed umbilical cord 
clamping puts newborns at a higher risk of suffering from polycythemia, respiratory 
distress, hyperbilirubinemia, and other neonatal disorders20.
A RCT conducted by Andersson et al. (2011)21 has compared early clamping 
(within 10 seconds after birth) and late clamping (to 180 seconds after birth) in 400 
term newborns. At 2 days after birth the study showed a prevalence of a significantly 
lower anaemia in the second than the first group. After 4 months haemoglobin 
values were equal in the 2 groups, even if ferritin levels were lower in babies with 
early clamping.
So, timing of cord clamping is an open question for obtaining a high concentration 
of stem cells needed for altruistic donation or private conservation.
No doubt the late clamping of the umbilical cord is necessary and recommended in 
premature newborns and in developing countries to allow a protracted placental 
perfusion before clamping and obtain a physiological normovolemia and a 
considerable iron transfer (about 30 mg) at birth22.
Moreover, according to data reported by Navarrete at the “World Cord Blood 
Congress III: Cord Blood Transplantation and Immunology of Haematopoietic Stem 
Cell Transplantation” (Rome, 27 - 29 October 2011) related to about 600.000 
collected samples in public banks, no serious diseases have been recorded or 
18 Hutton EK, Hassan ES, »Late vs Early Clamping of the Umbilical Cord in Full-term Neonates: systematic re-
view and meta-analysis of controlled trials«, JAMA, 2007, 297: 1241-52; Chaparro CM, Neufeld LM, Tena Alavez 
G, et al, »Effect of timing of umbilical cord clamping on iron status in Mexican infants: a randomised controlled 
trial«, Lancet, 2006, 367: 1997-2004.
19 Baenziger O, Stolkin F, Keel M et al, »The Influence of the Timing of Cord Clamping on Postnatal Cerebral 
Oxygenation in Preterm Neonates: A randomized, Controlled Trial«, Pediatrics, 2007, 119: 455-9.
20 Hutton EK, Hassan ES, »Late vs Early Clamping of the Umbilical Cord in Full-term Neonates: systematic 
review and meta-analysis of controlled trials«, JAMA, 2007, 297: 1241-52.
21 Andersson O, Hellstrom-Westas L, Andersson D et al, »Effect of delayed versus early umbilical cord clamping 
on neonatal outcomes and iron status at 4 months: a randomized controlled trial«, BMJ, 2011, 343: 7157.
22 Kinmond S, Aitkison TC, Holland BM et al, »Umbilical cord clamping and preterm infants: a randomized 
trial«, BMJ, 1993, 306(Jan): 172-5.
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described in newborns after cord clamping, which probably occurred about 60 
seconds after childbirth 23.
Thus, a time of clamping not less than 60 seconds after childbirth appears to be the 
recommended time to protect the newborn’s health, even if this could go to the 
detriment of a collection of an adequate amount of cord blood.
2.  Validity of informed consent
A second ethical requirement for the use of any treatment is an autonomous choice 
(principle of respect for autonomy). This argument is clearly connected to topic of 
informed consent (IC), i.e the act of an individual exercising a free and aware choice 
about whether or not to participate in research or to undergo medical treatment.
In the context of the UCB use, some key aspects of IC are: what information; who is 
the owner of the umbilical cord and thus the “donor” (mother or baby), and who is 
empowered to give consent on behalf of him (including competence for 
understanding and decision); for which purpose collecting UCB stem cells, whether 
for an altruistic intention (allogeneic and/or research) or for any personal autologous 
use in the future.24.
A consent to be valid should be “informed, free, express, specific and documented”25 
and it should be fundamentally characterized by four elements: the provision of 
information, understanding of information, freedom of decision, the decision-
making capacity26.
The information is critical to the decision-making of the patient and it should be as 
truthful and complete, to ensure to the person to choose freely and consciously. The 
principle of respect for autonomy implies, in fact, the right to give consent, based 
on full and transparent information.
This is the crux of the ethical controversies: if IC is defined as “a process by which a 
subject voluntarily confirms its willingness to participate in a particular trial, after 
having been informed of all aspects of the process that are relevant to the individual’s 
decision to participate”26, how could a choice be “free” and the consent really 
23 Navarrete C, »Review of International Fees for the provision of cord blood units«, World Cord Blood Congress 
III, October 27-29, 2011, ABS: 28.
24 Petrini C, »Umbilical cord blood collection, storage and use: ethical issues« Blood Transfus, 2010, 8: 139-48. 
Sacchini D, Pennacchini M, »Informed consent«, Clin Ter, 2010, 161: 397-9.
25 Art. 14, comma 1 of Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Bio-
medical Research, http://conventions.coe.int/Treaty/en/Treaties/Html/195.htm (19 March 2015).
26 Russo G, »Consenso informato. Dimensioni generali« in: Russo G (ed). Enciclopedia di Bioetica e Sessuologia. 
Leumann (TO): Elledici; 2004, pp. 524-526
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“informed” in such situations of misleading and incorrect information? What would 
be an adequate information?
With reference to the autologous collection, the American Academy of Pediatrics27 
and the American College of Obstetricians and Gynaecologists 28 doubts the validity of 
IC obtained by private banks, whose marketing strategy sometimes uses a 
particularly aggressive advertising approach. Websites, representatives, brochures/
flyers using messages, advertisements and images (eg: happy moments of a family, 
beautiful and smiling children, etc ...), which aim to arouse emotions in the subject 
who sees or hears them, in an attempt to involve the expectant parents in a choice 
that would be especially emotional. 
These private banks mention frequently as their “rationale” the hypothesis that 
future treatment programs for tissue repair/replacement will be developed (including 
heart, nervous system, liver, etc.).
Advertising declarations like “a once in a lifetime opportunity”, “storing your baby’s 
umbilical cord blood could save their life”, and “don’t let a precious resource go to 
waste”29 are misleading, because they promise to “close in the safe” the umbilical 
cord as a kind of biological insurance, creating in parents the illusion that the cord 
blood can represent a kind of therapeutic panacea for every disease and, at the same 
time, generate guilt, especially for those mothers who cannot buy a “hope for life” 
for their child30.
This creates a real “business of hope”, which preys on the desire of parents to give 
their child every advantage, and their concern about the real and hypothetical risks 
of future diseases for the child, on the particular emotional state of psychological 
vulnerability that characterizes the period of pregnancy. 
Actually, the scientific evidence affirms a greater “biological life insurance” in UCB 
donation for allogeneic use – that is accessible to anyone who needs it and actually 
used for several thousands of patients each year, with a good chance to find one’s 
own donated UCB unit in case of need - rather than save it for future personal 
therapeutic applications, today still hypothetical and not well-defined.
27 American Academy of Pediatrics, Pediatrics Group Recommends Public Cord Blood Banking, JAMA, 2007, 297: 
576.
28 ACOG committee opinion number 399, February 2008, »Umbilical cord blood banking«, Obstet Gynecol, 
2008,111:475–7.
29 Sullivan MJ, »Banking on cord blood stem cells«, Nat Rev Cancer, Jul 2008, 8(7):555-563.
30 Klingebiel T, »The Price of Hope«, Dtsch Arztebl Int, 2009, 106(50): 829–30.
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The American Society for Blood and Marrow Transplantation (2008)31 agrees with it: 
in fact, it criticized UCB collection and preservation for personal use, pointing out 
the remote chance of using one’s own UCB collected at the birth (probably between 
0,04% and 0,0005% in the first 20 years of life).
Two studies – Capone et al (2010)32 and Rebulla and Lecchi (2011)33 - have 
analysed the contents of different private cord blood banks websites, , finding 
sometimes misleading, deceptive, and unclear information. Several national and 
international documents emphasize the need for an accurate and adequate 
information.
Recommendation Rec(2004)8 of the Council of Europe34 emphasizes this aspect: 
«Accurate information should be provided to the population about the advantages 
and disadvantages of cord blood banks. Where autologous cord blood banks are 
being established, the promotional material or information provided to families 
must be accurate, and fully informed consent to cord blood storage must be 
obtained».
The European Group on Ethics in Science and New Technologies35 (EGE), regarding 
the need to provide accurate and truthful information, reports: “If commercial 
banks are allowed (in any EU member state), appropriate information should be 
given to consumers willing to use their services, including the fact that the likelihood 
that samples may be used to treat one’s child is currently negligible, that future 
therapeutic possibilities are of a very hypothetical nature, and that up until now 
there is no indication that the present research will lead to s,pecific therapeutic 
applications on one’s own cord blood cells.”; and also “...information should be 
particularly explicit, that the auto conservation has little value in the current state of 
scientific knowledge. This information should be made clear on all media, including 
Internet, and in any contracts linking commercial banks to their customers”.
IC also raises the question on who is the owner of the UCB, and therefore, who 
should give the consent (only the mother, or the father as well). On this matter, 
Petrini has showed two opposing positions: some suggest that the cord blood sample 
31 Ballen KK, »ASBMT Committee Report - Collection and Preservation of Cord Blood for Personal Use«, Biol 
Blood Marrow Transplant, 2008, 14:356-363.
32 Capone F, Lombardini L, Pupella S et al, »Cord blood stem cell banking: a snapshot of the Italian situation«, 
Transfusion, 2011, Sep;51(9):1985-94.
33 Rebulla P, Lecchi L, »Towards responsible cord blood banking models«, Cell Prolif, 2011, 44 (Suppl. 1): 30–4.
34 Council Of Europe: Committee of Ministers, Recommendation Rec(2004)8 of the Committee of Ministers to 
member States on autologous cord blood banks, (2004), https://wcd.coe.int/ViewDoc.jsp?id=744641&Lang=en (19 
March 2015).
35 European Group on Ethics in Science and New Technologies, Opinion 19, Ethical aspects of umbilical cord 
blood banking. (16 March 2004). http://ec.europa.eu/bepa/european-group-ethics/docs/avis19_en.pdf. (19 March 
2015).
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is the property of the child since it is developmentally, biologically and genetically 
part of the child; others affirm that it is the mother’s property once the cord is cut.
In any case, the expression of autonomy becomes problematic if establishing who is 
the “autonomous agent” is controversial36. The mother is usually required to give 
consent, but - if it is accepted that the cord blood belongs to the baby - it should be 
considered that the mother does not consent for herself, but on behalf of the baby. 
Moreover, she shares parental authority with the father. Therefore, the father’s 
involvement in the consent process is highly recommendable.
On this matter, Salvaterra’s approach to the question is appreciable: she affirms that 
a “participatory approach” could be the key to understand the process of donation 
implying a plurality of actors (pregnant women, future parents, donors, health 
professionals and institutions), that have different experiences and values. In this 
complex situation, implementing an intimate relationship between knowledge and 
choice guarantees conditions for a good service to the “person”37. 
It clearly shows how both the knowledge of decision-making processes applied to 
cord blood donation and the comprehension of underlying motivations might 
orient institutions, health professionals and public organisations to develop 
guidelines, that recommend for providing an accurate information on cord blood 
donation.
A suggestion could be to start the process of IC long before the birth, so that parents 
have more time to make a free and responsible decision. In any case, it should not 
be requested just before childbirth. 
Moreover, IC should be presented in a standardized form (i.e., a signed written 
statement, with no technical or confusing language, and not accepted in haste, 
etc.)38 and obtained by trained healthcare workers and not from parties with any 
conflicts of interest, especially economic ones, which, for example, may recommend 
the UCB collection for autologous use because they are employees of private banks. 
36 Stewart CL, Aparicio LC and Kerridge IH, »Ethical and legal issues raised by cord blood banking — the chal-
lenges of the new bioeconomy«, Med J Aust, 2013, 199 (4): 290-292.
37 Salvaterra E, Casati S, Bottardi S et al, »An analysis of decision making in cord blood donation through a 
participatory approach«, Transfus Apher Sci, 2010, 42: 299–305.
38 Petrini C, »Umbilical cord blood collection, storage and use: ethical issues«, Blood Transfus, 2010, 8: 139-48.
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3.  Economic issue in private UCB banking
A further requirement for ascertaining whether the use of any treatment is ethically 
acceptable is to assess if it is compatible with the principle of justice. Within the 
context of UCB use, this argument is connected to the economic issue in UCB 
banking, especially in private banking.
The economic factor present in the UCB private banking will be analysed not only 
in terms of the profits, but also in terms of the storage costs in charge of the parents.
Public and private UCB banking is widely debated from a scientific and ethical 
point of view. In a paper39, Rebulla and Lecchi have analysed and discussed their 
differences (cf. Table IV), also considering several ethical issues closely related to 
technical aspects: minimum cell dose per unit in inventory, techniques for UCB 
unit volume reduction, number of aliquots per banked unit, liquid versus vapour 
nitrogen storage, UCB unit overwrapping, proportion of ethnic minorities in 
inventory, reimbursement fee per transplanted patient versus per distributed UCB 
unit. 
Table IV - Main differences between public and private banking
39 Rebulla P, Lecchi L, »Towards responsible cord blood banking models«, Cell Prolif, 2011, 44 (Suppl. 1): 30–4.
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Regarding to the issue “for profit”, Article 21 of Convention of Oviedo states “The 
human body and its parts shall not, as such, give rise to financial gain.”40 
Additionally, Article 2 of Additional Protocol to the Convention on Human Rights and 
Biomedicine concerning Transplantation of Organs and Tissues of Human Origin41 says 
“The provisions of this Protocol applicable to tissues shall apply also to cells, 
including haematopoietic stem cells”. This is stated by Article 3 of Charter Of 
Fundamental Rights Of The European Union42 “The prohibition on making the 
human body and its parts as such a source of financial gain” and by Article 7 of 
Recommendation Rec(2006)4 43 of The Committee of Ministers to Member States on 
Research on Biological Materials of Human Origin “Biological materials should not, 
as such, give rise to financial gain”. 
Within the national and European legal framework, the prohibition of human body 
marketing is established. Under this rule, the tissues – and also stem cells - are 
considered extra commercium goods and, therefore, cannot be a source of profit. 
Subjecting the body to commercialization would be detrimental to human dignity, 
as a result the private UCB banks led explicitly by a for profit logic, are an 
undeniable ethical critical issues. Just as you cannot buy or sell blood or organs, you 
should not take undue profit from UCB stem cell storage.
On the contrary, private banks are now all over the world and have increased in 
number in recent years, becoming a real “industry” and transforming cord blood 
from a biological resource into an important bio-economic resource. This is reported 
in Capitalizing on Opportunities in Cord Blood Industry Growth44, an industry-
report that highlights how the UCB banks represent an opportunity for profit and 
competition and provides tools to learn and study not only the market and future 
perspectives, but also the “expectations of potential customers” (i.e. expectant 
parents) to better define market strategies and monitor competitiveness.
40 Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of 
Biology and Medicine: Convention on Human Rights and Biomedicine. Oviedo 1997). http://conventions.coe.int/
Treaty/en/Treaties/Html/164.htm (19 March 2015).
41 Additional Protocol to the Convention on Human Rights and Biomedicine concerning Transplantation of Organs 
and Tissues of Human Origin. Strasbourg, 2002. http://conventions.coe.int/treaty/en/treaties/html/186.htm (19 
March 2015).
42 Charter Of Fundamental Rights Of The European Union. 2010. http://eur-lex.europa.eu/LexUriServ/Lex-
UriServ.do?uri=OJ:C:2010:083:0389:0403:en:PDF (19 March 2015).
43 Council of Europe: Committee of Ministers. Recommendation Rec(2006)4 of the Committee of Ministers to 
member states on research on biological materials of human origin. https://wcd.coe.int/ViewDoc.jsp?id=977859 (19 
March 2015).
44 http://www.marketresearch.com/BioInformant-Worldwide-L-C-v3663/Capitalizing-Opportunities-Cord-
Blood-Growth-7863251/ (19 March 2015); http://www.bioinformant.com/category/cord-blood/ (19 March 
2015).
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It is clear that public and private UCB banks are the expression of two different 
approaches: the model of social justice, which postulates the right to health as a 
fundamental human right and promotes solidarity between citizens through the 
philosophy of voluntary and free donation45, and the model of supply and demand, 
pointing instead to a liberal interpretation of the parents’ autonomy.
So, the bioethical debate is between the principle of social solidarity and the rights 
of individual freedom. Private banking, based on individualism and the principle of 
respect for individual autonomy, could introduce, therefore, more than one variable 
of social discrimination and go against the realization of the “common good”.
A first discrimination is linked to the costs paid by the parents for the private storage 
of UCB samples. This could be also source of possible inequality between the rich 
and the poor and so private banking could become a prerogative only for wealthier 
households. This could represent a violation of the individual’s right to a fair access 
to health care.
Moreover, choosing private banking - in view of hypothetical future therapeutic 
autologous use - could deprive patients, both children and adults, of access to a 
considerable amount of blood units, and consequently, of higher chances of cure. 
We must not forget that not all can find suitable donors within existing international 
registries. In particular, the likelihood of finding a donor varies across racial/ethnic 
groups and this variation is due to under-representation of some ethnic groups 
within donor registries and to increased HLA diversity within some ethnic groups.
Another important limitation of private UCB banking is the variability in quality 
standards unlike public UCB banking that use specific standard operating protocols 
and must meet international criteria and requirements, including adequate cell 
count and volume. In fact, rigorous donor screening and infectious disease testing 
might not be required in private UCB banking as in public banks46.
45 Sykora P, »Altruism in Medical Donations Reconsidered: the Reciprocity Approach« in: Steinmann M, Sykora 
P, Wiesing U (eds),.Altruism Reconsidered. Exploring New Approaches to Property in Human Tissue. Ashgate: Farn-
ham-Burlington, 2009, pp 13-49; Hoppe N, »A Sense of Entitlement: Individual vs. Public Interest in Human 
Tissue« in: Lenk C, Sándor J, Gordijn B (eds). Biobanks and Tissue Research. The Public, the Patient and the Regula-
tion. Heidelberg London New York: Springer Dordrecht, 2011, pp. 53-64. Titmuss RM. The Gift Relationship: 
From Human Blood to Social Policy. London: George Allen & Unwin Ltd, 1970.
46 Sun J, McLaughlin C, Sledge L et al, »Differences in quality between privately and publicly banked umbilical 
cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders«, 
Transfusion, 2010, 50:1980–7; ACOG Committee Opinion n 399, »Umbilical cord blood banking«,. Obstet Gy-
necol, 2008,111:475–7; Cord Blood Working Group, »Combined private and public banking of cord blood and 
other related products«, Leiden, NL: World Marrow Donor Association, 2012. http://www.worldmarrow.org/filead-
min/Committees/Cord_Blood_Working_Group/20120328-CBWG-PPR-Hybrid.pdf (19 March 2015).
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Under the pressure of financial incentives, private UCB banks typically store the 
UCB regardless of its quality and do not provide quality reports on the UCB unit 
(including such metrics as the cell dose collected and the viability of the cells) to the 
client. So, there is a reasonable possibility that UCB units stored in private banks 
could be considered substandard and not be able to assure an adequate quality and, 
therefore, could be therapeutically ineffective when donors seek to use their UCB47.
Another critical point is the collection of the sample that in private UCB collections 
may be performed by medical or nursing personnel with limited experience in 
UCB48.
On the contrary, public UCB banking considers cord blood as a “common good” 
just like blood and organs and through it the access to benefits related to “life 
saving” availability (such as blood transfusion, cell therapy and organ 
transplantation) could be ensured for all individuals in need49.
The “common good” can be defined as “the good of all and of each”50 and in this 
perspective it should ensure equal treatment respecting the equal dignity of all 
human beings and the different needs of each person relating to their state of health 
or disease. Promoting the common good is promoting the good of each51.
In light of the fact that today only a small amount of donations collected in public 
banks are used for transplantation, this means that in the case where an altruistic 
donor needs an autologous transplant, he/she may find their own cord blood unit 
still available52.
As already mentioned, to 2015 more than 600.000 UCB units were banked in 
about 120 public banks worldwide for “public” use, but these impressive numbers 
are insufficient to satisfy all the medical needs for UCB, so additional efforts are 
required to ensure that all patients, including ethnic minorities, can promptly find a 
suitable donor53.
47 Moises Serrano-Delgado V, Novello-Garza B, Valdez-Martinez E, »Ethical issues relating to the banking of 
umbilical cord blood in Mexico«, BMC Medical Ethics, 2009, 10:12; Sun J, Allison J, Mc Laughlin C et al. »Dif-
ferences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous 
cord blood infusion in children with acquired autologous disorders«, Transfusion, 2010,50:1980-7.
48 Butler MG, Menitove JE, »Umbilical cord blood banking: an update«, J Assist Reprod Genet, 2011, 28:669–76.
49 Sacchini D, Liumbruno GM, Bruno G et al, »Ethical and deontological issues in Transfusion Medicine«, Blood 
Transfus, 2013,11:14-25.
50 S. Vanni Rovighi, Istituzioni di filosofia, Brescia: La Scuola, 1982, p. 150.
51 Sgreccia E, Manuale di bioetica. I. Fondamenti ed etica biomedica, Milano: Vita e Pensiero, 2007: 227-228.
52 Fox NS, Chervenak FA, McCullough LB, »Ethical considerations in umbilical cord blood banking«, Obstet 
Gynecol, 2008, 111:178–82.
53 Gluckman E, Ruggeri A, Volt F et al, »Milestones in umbilical cord blood transplantation«, Br J Haematol, 
2011, 154 (4):441-7; http://www.bmdw.org (19 March 2015); Rebulla P, Lecchi L. »Towards responsible cord 
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As highlighted by Rebulla e Lecchi54, the first responsibility of all stakeholders 
(governments, clinicians, scientists, patients, and industry) should be the promotion 
of altruistic UCB donation and development of UCB banking models able to fully 
meet all patients’ needs.
Regarding private banking for an autologous use, at present indications for 
autologous UCB transplantation are restricted to few specific diagnoses (for example 
childhood cancer)55. 
Eventual additional indications for autologous UCB transplantation and the 
promising development of new therapies in regenerative medicine, together with 
the data concerning the limited funding available for public UCB banks, could lead 
to re-assessing private UCB banking. 
4.  Hybrid banking: solution or compromise?
On this matter, it should be noted that recently combined (or ‘‘hybrid’’) public/
private UCB banking is emerging in some countries and also this solution could be 
taken into account. 
To date, two models of hybrid bank begin to appear: the “sequential” model and the 
“splitting” model56.
The “sequential” model is characterized by two subsequent steps: at first the UCB 
unit is privately stored, HLA typed and anonymously registered in the international 
stem cell registry; later, only if the UCB unit is requested for the allogeneic 
transplantation for an unrelated, parents are asked again to release their consent. If 
parents decide to consent to donate their UCB unit, they would be reimbursed the 
costs incurred for the private banking. One of the limitations of this model is that it 
could frustrate the parents’ desire to keep UCB for their child.
blood banking models«, Cell Prolif, 2011, 44 (Suppl. 1): 30–4.
54 Rebulla P, Lecchi L, »Towards responsible cord blood banking models«,Cell Prolif, 2011, 44 (Suppl. 1): 30–4.
55 Rosenthal J, Woolfrey AE, Pawlowska, A et al, »Hematopoietic Cell Transplantation With Autologous Cord 
Blood in Patients With Severe Aplastic Anemia: An Opportunity to Revisit the Controversy Regarding Cord 
Blood Banking for Private Use«, Pediatr Blood Cancer, 2011, 56: 1009–12.
56 Wagner AM, Krenger W, Suter E et al, »High acceptance rate of hybrid allogeneic-autologous umbilical cord 
blood banking among actual and potential Swiss donors«, Transfusion, 2013, 53(7):1510-9; O’Connor MA, Sam-
uel G, Jordens CF et al, »Umbilical cord blood banking: beyond the public-private divide«, Transfusion, 2013, 
53(7):1510-9; Manegold G, Meyer-Monard S, Tichelli A et al, »Controversies in hybrid banking: attitudes of 
Swiss public umbilical cord blood donors toward private and public banking«, Arch Gynecol Obstet, 2011, 284: 
99–104; Petrini C, »Ethical issues in umbilical cord blood banking: a comparative analysis of documents from 
national and international institutions«, Transfusion, 2013, 53: 902-10; Parco S, Vascotto F, Visconti P, »Public 
banking of umbilical cord blood or storage in a private bank: testing social and ethical policy in northeastern Italy«, 
J Blood Med, 2013, 4:23–9.
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In “splitting” model, adopted by the Virgin Health Bank57 in the UK, 80% of the 
initial UCB unit is stored in the public inventory and 20% for private use. One of 
the limitations of this model is related to the possibility of a low cellularity following 
the separation of the sample into two portions that could make samples unsuitable 
for transplantation58.
In a recent prospective survey, Wagner et al.59 have investigated the acceptance of 
hybrid UCB banking among actual and potential UCB donors by comparing a 
group of parents and pregnant women (with or without children) with a group of 
women at reproductive ages.
One of the most interesting emerged data is that the majority (49% overall) would 
prefer the hybrid model if such an option was available60.
Nevertheless, ethical issues are also present in hybrid banking: the need to ensure 
sample quality by adopting international quality standards; to determine the sample 
ownership (bank or parents?); to provide adequate and impartial information, and 
to obtain a true IC from parents.
Conclusion: Towards a culture of “donation”
UCB stem cells offer the possibility to treat a wide range of diseases. However, their 
use raises some ethical issues. Following the well-known basic ethical principles for 
biomedicine (i.e. beneficence/non maleficence, autonomy and justice) as 
methodological reference, it is possible to highlight that: 1) allogeneic UCB use, 
compared to the autologous UCB use, seems fulfil better the principle of 
beneficence/non maleficence as it provides logistical and clinical benefits and it 
decreases risks; 2) acquisition of IC requires an adequate counselling, particularly 
for what concerns autologous collection; 3) public UCB banking seems to fulfil the 
criteria for justice more than private banking. 
Beyond these considerations, the implementation of this new therapeutic possibility 
for treating a wide variety of diseases needs a culture of “donation” and a “solidarity 
chain”61 between donors and recipients as background. Donation is an exercise of 
57 Branson R, »World’s first public-private cord blood bank launched in UK«, BMJ, 2007, 334(7587): 229.
58 Guilcher GM, Fernandez CV, Joffe S, »Are hybrid umbilical cord blood banks really the best of both worlds?«, 
J Med Ethics, 2015, 41(3):272-5.
59 Wagner AM, Krenger W, Suter E et al, »High acceptance rate of hybrid allogeneic-autologous umbilical cord 
blood banking among actual and potential Swiss donors«, Transfusion, 2013, 53(7):1510-9.
60 Ibid, pp. 1510-9.
61 Rebulla P, Lecchi L, »Towards responsible cord blood banking models«, Cell Prolif, 2011, 44 (Suppl. 1): 30–4.
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freedom and of responsibility, and an investment in the other, in the world, in 
human possibilities.
For this reason, policies that provide opportunities for all women to donate UCB 
should be implemented, increasing the culture of “donation” through educational 
outreach: this is the main ethically feasible way to guarantee respect for each person’s 
responsible choices in society and to effectively promote donation as a noble act of 
human solidarity62.
An alternative that should be explored is “hybrid” banking, because it could 
combine together the respect for individual autonomy, that would respect his/her 
right to choose autologous UCB storage, with solidarity towards those in need that 
is at the base of allogeneic donation. Further reflection is needed, as this new model 
of banking raises further ethical issues, that are closely related to private/public 
UCB banking ones. Additionally, this new “combined” public-private model would 
increase the number of available UCB units for addressing the ever-increasing 
number of patients requiring UCB transplantation and could lighten the economic 
difficulties of many countries.
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Alogeno naspram autolognog: etička 
pitanja pri uporabi krvi iz pupčane vrpce
SAŽETAK
Cilj: Analizirati etička pitanja vezana uz prikupljanje, skladištenje i upotrebu krvi prikupljene 
iz pupčane vrpce.
Materijali i metode: Etička pitanja postavljena su u odnosu na temeljna etička načela u 
biomedicini: dobročinstva/neškodljivosti, poštovanja autonomije i pravde. Specifična pitanja 
o kojima se raspravlja tiču se kliničke korisnosti autologne uporabe krvi iz pupčane vrpce u 
usporedbi s korištenjem alogena za transplantaciju, valjanost informiranog pristanka, posebno 
kod privatnog pohranjivanja krvi iz pupčane vrpce, te kontroverzno pitanje pohrane krvi iz 
pupčane vrpce u svrhu profita u usporedbi s neprofitnim pohranjivanjem.
Rezultati: Naša etička analiza pokazala je kako je alogena upotreba krvi iz pupčane vrpce u 
transplantaciji, za razliku od autologne uporabe, ispunila principe dobročinstva/neškodljivosti 
jer pruža logističke i kliničke prednosti te smanjuje rizik. Pri dobivanju informiranog 
pristanka potrebna su dodatna savjetovanja, osobito za autologne materijale. Konačno, 
javno skladištenje krvi iz pupčane vrpce ispunjava kriterije pravednosti više nego privatno 
skladištenje.
Zaključak: Trenutne i buduće terapeutske mogućnosti koje nudi krv iz pupčane vrpce u 
liječenju bolesti pokazatelj su veće potrebe za krvlju iz pupčane vrpce, stoga je potrebno 
razvijati kulturu poklanjanja i solidarnosti između darivatelja i primatelja. Unazad nekoliko 
godina pojavio se koristan model skladištenja krvi, tzv. „hibridno” skladištenje.
Ključne riječi: etika, alogeno, autologno
